Carlos Martin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8614225/publications.pdf

Version: 2024-02-01

179 papers	12,708 citations	36691 53 h-index	31191 106 g-index
192 all docs	192 docs citations	192 times ranked	8070 citing authors

#	Article	IF	Citations
1	The Mycobacterium tuberculosis PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy. Molecular Therapy - Nucleic Acids, 2022, 27, 1235-1248.	2.3	10
2	Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. , 2022, 10, e004325.		4
3	Engineering a new vaccine platform for heterologous antigen delivery in live-attenuated Mycobacterium tuberculosis. Computational and Structural Biotechnology Journal, 2021, 19, 4273-4283.	1.9	4
4	MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. Npj Vaccines, 2021, 6, 4.	2.9	23
5	Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment. EBioMedicine, 2021, 64, 103186.	2.7	8
6	Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG. Frontiers in Immunology, 2021, 12, 622995.	2.2	14
7	BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies. EBioMedicine, 2021, 65, 103254.	2.7	10
8	MTBVAC, a live TB vaccine poised to initiate efficacy trials 100Âyears after BCG. Vaccine, 2021, 39, 7277-7285.	1.7	31
9	Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. Science Immunology, 2021, 6, eabc2934.	5.6	27
10	Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. Cell Reports Medicine, 2021, 2, 100185.	3.3	41
11	Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Reports Medicine, 2021, 2, 100187.	3.3	26
12	TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). Human Vaccines and Immunotherapeutics, 2021, 17, 4299-4327.	1.4	0
13	Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euroâ€“American genetic background confers optimal vaccine potential. EBioMedicine, 2020, 55, 102761.	2.7	22
14	Update on TB Vaccine Pipeline. Applied Sciences (Switzerland), 2020, 10, 2632.	1.3	38
15	Respiratory Immunization With a Whole Cell Inactivated Vaccine Induces Functional Mucosal Immunoglobulins Against Tuberculosis in Mice and Non-human Primates. Frontiers in Microbiology, 2020, 11, 1339.	1.5	11
16	New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathogens, 2020, 16, e1008404.	2.1	58
17	Independent genomic polymorphisms in the PknH serine threonine kinase locus during evolution of the Mycobacterium tuberculosis Complex affect virulence and host preference. PLoS Pathogens, 2020, 16, e1009061.	2.1	4
18	Title is missing!. , 2020, 16, e1009061.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 16, e1009061.		0
20	Title is missing!. , 2020, 16, e1009061.		0
21	Title is missing!. , 2020, 16, e1009061.		0
22	Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis. Veterinary Research, 2019, 50, 82.	1.1	22
23	Construction and Characterization of the Mycobacterium tuberculosis sigE fadD26 Unmarked Double Mutant as a Vaccine Candidate. Infection and Immunity, 2019, 88, .	1.0	5
24	Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respiratory Medicine,the, 2019, 7, 757-770.	5.2	92
25	Mycobacterial Aminoglycoside Acetyltransferases: A Little of Drug Resistance, and a Lot of Other Roles. Frontiers in Microbiology, 2019, 10, 46.	1.5	28
26	Mycobacterium tuberculosis infection prevents asthma and abrogates eosinophilopoiesis in an experimental model. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2512-2514.	2.7	6
27	Comparative Metabolomics between Mycobacterium tuberculosis and the MTBVAC Vaccine Candidate. ACS Infectious Diseases, 2019, 5, 1317-1326.	1.8	16
28	A Mycobacterium tuberculosis Beijing strain persists at high rates and extends its geographic boundaries 20 years after importation. Scientific Reports, 2019, 9, 4687.	1.6	11
29	MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice. Molecular Therapy - Methods and Clinical Development, 2019, 13, 253-264.	1.8	14
30	Breaking Transmission with Vaccines: The Case of Tuberculosis. , 2019, , 249-261.		0
31	Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines. Nature Communications, 2019, 10, 5457.	5.8	6
32	VacunaciÃ³n frente a tuberculosis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 648-656.	0.3	4
33	Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer. Translational Research, 2018, 197, 32-42.	2.2	9
34	Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3238-E3245.	3.3	36
35	New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages. PLoS Genetics, 2018, 14, e1007282.	1.5	57
36	Vaccination against tuberculosis. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 648-656.	0.2	3

#	Article	IF	Citations
37	IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine. Mucosal Immunology, 2018, 11, 1753-1762.	2.7	55
38	MTBVAC from discovery to clinical trials in tuberculosis-endemic countries. Expert Review of Vaccines, 2017, 16, 565-576.	2.0	48
39	Evaluation of the Mycobacterium tuberculosis SO2 vaccine using a natural tuberculosis infection model in goats. Veterinary Journal, 2017, 223, 60-67.	0.6	14
40	Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis. Journal of Infectious Diseases, 2017, 216, 525-533.	1.9	33
41	Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nature Communications, 2017, 8, 16085.	5.8	109
42	MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. Frontiers in Immunology, 2017, 8, 1803.	2.2	70
43	Detection of a Putative TetR-Like Gene Related to Mycobacterium bovis BCG Growth in Cholesterol Using a gfp-Transposon Mutagenesis System. Frontiers in Microbiology, 2017, 8, 315.	1.5	1
44	Breaking Transmission with Vaccines: The Case of Tuberculosis. Microbiology Spectrum, 2017, 5, .	1.2	6
45	Tuberculosis Vaccines. , 2017, , 149-160.		0
46	In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain. Tuberculosis, 2016, 100, 46-52.	0.8	9
47	Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice. Journal of Visualized Experiments, 2016, , .	0.2	10
48	Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. Journal of Infectious Diseases, 2016, 214, 659-664.	1.9	45
49	Sulphonamide resistance associated with integron derivative Tn6326inActinotignum schaalii. Journal of Antimicrobial Chemotherapy, 2016, 71, 2670-2671.	1.3	4
50	Mycobacterial diversity causing multi- and extensively drug-resistant tuberculosis in Djibouti, Horn of Africa. International Journal of Tuberculosis and Lung Disease, 2016, 20, 150-153.	0.6	6
51	MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis, 2016, 96, 71-74.	0.8	46
52	Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17â€"Dependent Mechanism. Journal of Infectious Diseases, 2016, 213, 831-839.	1.9	120
53	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo. PLoS ONE, 2016, 11, e0153028.	1.1	10
54	On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines. PeerJ, 2016, 4, e1513.	0.9	18

#	Article	IF	Citations
55	Klebsiella pneumoniaesurvives within macrophages by avoiding delivery to lysosomes. Cellular Microbiology, 2015, 17, 1537-1560.	1.1	116
56	Editorial Commentary: Nonspecific Beneficial Effects of BCG Vaccination in High-income Countries, Should We Extend Recommendation of BCG Vaccination?. Clinical Infectious Diseases, 2015, 60, 1620-1621.	2.9	8
57	Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respiratory Medicine,the, 2015, 3, 953-962.	5.2	148
58	In Vivo IS 6110 Profile Changes in a Mycobacterium tuberculosis Strain as Determined by Tracking over 14 Years. Journal of Clinical Microbiology, 2015, 53, 2359-2361.	1.8	5
59	Evolutionary Landscape of the Mycobacterium tuberculosis Complex from the Viewpoint of PhoPR: Implications for Virulence Regulation and Application to Vaccine Development. MBio, 2015, 6, e01289-15.	1.8	71
60	Evaluation of the immunogenicity and diagnostic interference caused by M. tuberculosis SO2 vaccination against tuberculosis in goats. Research in Veterinary Science, 2015, 103, 73-79.	0.9	17
61	A Specific Polymorphism in Mycobacterium tuberculosis H37Rv Causes Differential ESAT-6 Expression and Identifies WhiB6 as a Novel ESX-1 Component. Infection and Immunity, 2014, 82, 3446-3456.	1.0	74
62	The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in Mycobacterium tuberculosis. PLoS Pathogens, 2014, 10, e1004183.	2.1	127
63	Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination. Vaccine Journal, 2014, 21, 594-597.	3.2	43
64	Single nucleotide polymorphism (SNP) analysis used for the phylogeny of the Mycobacterium tuberculosis complex based on a pyrosequencing assay. BMC Microbiology, 2014, 14, 21.	1.3	11
65	Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis. Cell Death and Disease, 2014, 5, e1343-e1343.	2.7	41
66	Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice. Vaccine, 2014, 32, 5192-5197.	1.7	24
67	Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11491-11496.	3.3	204
68	A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 397-406.	0.9	12
69	Mapping IS6110 in high-copy number Mycobacterium tuberculosis strains shows specific insertion points in the Beijing genotype. BMC Genomics, 2013, 14, 422.	1.2	43
70	ESX-1-induced apoptosis is involved in cell-to-cell spread ofMycobacterium tuberculosis. Cellular Microbiology, 2013, 15, 1994-2005.	1.1	116
71	Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine, 2013, 31, 4867-4873.	1.7	211
72	Recent developments in tuberculosis vaccines. Expert Review of Vaccines, 2013, 12, 1431-1448.	2.0	33

#	Article	IF	Citations
73	Global Study of IS6110in a Successful Mycobacterium tuberculosis Strain: Clues for Deciphering Its Behavior and for Its Rapid Detection. Journal of Clinical Microbiology, 2013, 51, 3631-3637.	1.8	15
74	ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question. Frontiers in Cellular and Infection Microbiology, 2013, 3, 88.	1.8	42
75	Rapid Test for Identification of a Highly Transmissible Mycobacterium tuberculosis Beijing Strain of Sub-Saharan Origin. Journal of Clinical Microbiology, 2012, 50, 516-518.	1.8	16
76	Functional and Genetic Characterization of the Tap Efflux Pump in Mycobacterium bovis BCG. Antimicrobial Agents and Chemotherapy, 2012, 56, 2074-2083.	1.4	63
77	IS-seq: a novel high throughput survey of in vivo IS6110 transposition in multiple Mycobacterium tuberculosis genomes. BMC Genomics, 2012, 13, 249.	1.2	29
78	Long-term molecular surveillance of multidrug-resistant tuberculosis in Spain. Infection, Genetics and Evolution, 2012, 12, 701-710.	1.0	18
79	Conspicuous multidrug-resistant Mycobacterium tuberculosis cluster strains do not trespass country borders in Latin America and Spain. Infection, Genetics and Evolution, 2012, 12, 711-717.	1.0	30
80	Protective immunity afforded by attenuated, PhoPâ€deficient Mycobacterium tuberculosis is associated with sustained generation of CD4⁺ Tâ€cell memory. European Journal of Immunology, 2012, 42, 385-392.	1.6	46
81	Attenuated Mycobacterium tuberculosis SO2 Vaccine Candidate Is Unable to Induce Cell Death. PLoS ONE, 2012, 7, e45213.	1.1	32
82	New tuberculosis vaccines. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 57-62.	0.3	9
83	The Transcriptional Regulatory Network of Mycobacterium tuberculosis. PLoS ONE, 2011, 6, e22178.	1.1	58
84	Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237. Tuberculosis, 2011, 91, 117-126.	0.8	47
85	Drug-resistant tuberculosis in the European Union: Opportunities and challenges for control. Tuberculosis, 2010, 90, 182-187.	0.8	21
86	High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling. PLoS Pathogens, 2010, 6, e1001100.	2.1	158
87	Uma nova vacina viva contra a tuberculose com base na inativaÃ§Ã£o do phoP. Revista Portuguesa De Pneumologia, 2010, 16, S43-S48.	0.7	1
88	Interactions of Attenuated Mycobacterium tuberculosis phoP Mutant with Human Macrophages. PLoS ONE, 2010, 5, e12978.	1.1	38
89	MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques. PLoS ONE, 2009, 4, e5264.	1.1	186
90	Human-to-Human Transmission of Tuberculosis Caused by Mycobacterium bovis in Immunocompetent Patients. Journal of Clinical Microbiology, 2009, 47, 1249-1251.	1.8	58

#	Article	IF	Citations
91	Multidrug-ResistantMycobacterium tuberculosisStrain from Equatorial Guinea Detected in Spain. Emerging Infectious Diseases, 2009, 15, 1858b-1860.	2.0	11
92	Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth. Antimicrobial Agents and Chemotherapy, 2009, 53, 3675-3682.	1.4	116
93	Unsuspected and extensive transmission of a drug-susceptible Mycobacterium tuberculosisstrain. BMC Pulmonary Medicine, 2009, 9, 3.	0.8	15
94	Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity. Microbes and Infection, 2009, 11, 115-122.	1.0	17
95	Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine, 2009, 27, 2499-2505.	1.7	47
96	Mapping of IS6110 insertion sites in Mycobacterium bovis isolates in relation to adaptation from the animal to human host. Veterinary Microbiology, 2008, 129, 333-341.	0.8	27
97	Attenuated strains of Mycobacterium tuberculosis complex for laboratory and clinical use. Tuberculosis, 2008, 88, 371-374.	0.8	2
98	Live tuberculosis vaccines based onphoPmutants: a step towards clinical trials. Expert Opinion on Biological Therapy, 2008, 8, 201-211.	1.4	36
99	A Point Mutation in the Two-Component Regulator PhoP-PhoR Accounts for the Absence of Polyketide-Derived Acyltrehaloses but Not That of Phthiocerol Dimycocerosates in Mycobacterium tuberculosis H37Ra. Journal of Bacteriology, 2008, 190, 1329-1334.	1.0	104
100	TheMycobacterium tuberculosis phoPROperon Is Positively Autoregulated in the Virulent Strain H37Rv. Journal of Bacteriology, 2008, 190, 7068-7078.	1.0	49
101	Control of M. tuberculosis ESAT-6 Secretion and Specific T Cell Recognition by PhoP. PLoS Pathogens, 2008, 4, e33.	2.1	234
102	PhoP: A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence. PLoS ONE, 2008, 3, e3496.	1.1	195
103	Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clinical and Experimental Immunology, 2007, 147, 330-338.	1.1	36
104	Multidrug-resistant Mycobacterium tuberculosis Beijing/W genotype in Venezuela. Journal of Medical Microbiology, 2007, 56, 1707-1708.	0.7	5
105	Transcriptional analysis of and resistance level conferred by the aminoglycoside acetyltransferase gene aac(2')-Id from Mycobacterium smegmatis. Journal of Antimicrobial Chemotherapy, 2007, 61, 39-45.	1.3	6
106	Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. Journal of Antimicrobial Chemotherapy, 2007, 59, 544-547.	1.3	51
107	Recurrent tuberculosis from 1992 to 2004 in a metropolitan area. European Respiratory Journal, 2007, 30, 333-337.	3.1	32
108	Spread of Extensively Drug-resistant Tuberculosis. Emerging Infectious Diseases, 2007, 13, 647-648.	2.0	21

#	Article	IF	Citations
109	Genotyping of Mycobacterium tuberculosis over two periods: a changing scenario for tuberculosis transmission. International Journal of Tuberculosis and Lung Disease, 2007, 11, 1080-6.	0.6	21
110	The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine, 2006, 24, 3408-3419.	1.7	193
111	Multidrug-resistantMycobacterium tuberculosis, Bangui, Central African Republic. Emerging Infectious Diseases, 2006, 12, 1454-1456.	2.0	16
112	Tuberculosis vaccines: past, present and future. Current Opinion in Pulmonary Medicine, 2006, 12, 186-191.	1.2	35
113	Neutral-red reaction is related to virulence and cell wall methyl-branched lipids in Mycobacterium tuberculosis. Microbes and Infection, 2006, 8, 183-190.	1.0	36
114	The use of mutant mycobacteria as new vaccines to prevent tuberculosis. Tuberculosis, 2006, 86, 203-210.	0.8	16
115	Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiology, 2006, 6, 23.	1.3	900
116	Molecular characterisation of Mycobacterium tuberculosis isolates in the First National Survey of Anti-tuberculosis Drug Resistance from Venezuela. BMC Microbiology, 2006, 6, 90.	1.3	39
117	Cefotetan-induced hemolytic anemia after perioperative prophylaxis. American Journal of Hematology, 2006, 81, 186-188.	2.0	7
118	The Virulence-associated Two-component PhoP-PhoR System Controls the Biosynthesis of Polyketide-derived Lipids in Mycobacterium tuberculosis. Journal of Biological Chemistry, 2006, 281, 1313-1316.	1.6	197
119	Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. Journal of Antimicrobial Chemotherapy, 2006, 57, 252-259.	1.3	65
120	Novel Streptomycin Resistance Gene from Mycobacterium fortuitum. Antimicrobial Agents and Chemotherapy, 2006, 50, 3920-3922.	1.4	29
121	Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis, 2005, 85, 29-38.	0.8	154
122	Systematic Molecular Characterization of Multidrug-Resistant Mycobacterium tuberculosis Complex Isolates from Spain. Journal of Clinical Microbiology, 2005, 43, 1220-1227.	1.8	40
123	The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?. European Respiratory Journal, 2005, 26, 162-167.	3.1	48
124	Revisiting the Evolution of Mycobacterium bovis. Journal of Bacteriology, 2005, 187, 6386-6395.	1.0	101
125	Molecular characterization of Mycobacterium tuberculosis complex isolates from wild ungulates in south-central Spain. Veterinary Research, 2005, 36, 43-52.	1.1	109
126	IS 6110 Mediates Increased Transcription of the phoP Virulence Gene in a Multidrug-Resistant Clinical Isolate Responsible for Tuberculosis Outbreaks. Journal of Clinical Microbiology, 2004, 42, 212-219.	1.8	130

#	Article	IF	Citations
127	Mycobacterium smegmatisdisplays theMycobacterium tuberculosisvirulence-related neutral red character when expressing theRv0577gene. FEMS Microbiology Letters, 2004, 231, 283-289.	0.7	18
128	Epidemiology of tuberculosis on Gran Canaria: a 4 year population study using traditional and molecular approaches. Thorax, 2003, 58, 618-622.	2.7	27
129	Mutations in Putative Mutator Genes ofMycobacterium tuberculosisStrains of the W-Beijing Family. Emerging Infectious Diseases, 2003, 9, 838-845.	2.0	240
130	The Multidrug Transporters Belonging to Major Facilitator Superfamily (MFS) in Mycobacterium tuberculosis. Molecular Medicine, 2002, 8, 714-724.	1.9	111
131	Molecular epidemiology of tuberculosis in Elche, Spain: a 7-year study. Journal of Medical Microbiology, 2002, 51, 273-277.	0.7	14
132	Mycobacterium tuberculosis phoP mutant: lipoarabinomannan molecular structure. Microbiology (United Kingdom), 2002, 148, 3029-3037.	0.7	63
133	The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Molecular Medicine, 2002, 8, 714-24.	1.9	56
134	Energy transfer between fluorescent proteins using a co-expression system in Mycobacterium smegmatis. Gene, 2001, 278, 115-124.	1.0	58
135	An essential role for phoP in Mycobacterium tuberculosis virulence. Molecular Microbiology, 2001, 41, 179-187.	1.2	363
136	High Rate of Tuberculosis Reinfection during a Nosocomial Outbreak of Multidrug-Resistant Tuberculosis Caused by Mycobacterium bovis Strain B. Clinical Infectious Diseases, 2001, 32, 159-161.	2.9	98
137	Epidemiological Evidence of the Spread of a Mycobacterium tuberculosis Strain of the Beijing Genotype on Gran Canaria Island. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1165-1170.	2.5	163
138	Characterization of P55, a Multidrug Efflux Pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2001, 45, 800-804.	1.4	117
139	Exogenous Reinfection with Tuberculosis on a European Island with a Moderate Incidence of Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 717-720.	2.5	142
140	Molecular characterization of mycobacteria isolated from seals. Microbiology (United Kingdom), 1999, 145, 2519-2526.	0.7	30
141	Usefulness of Spoligotyping in Molecular Epidemiology of Mycobacterium bovis -Related Infections in South America. Journal of Clinical Microbiology, 1999, 37, 296-303.	1.8	75
142	Comparison of Methods Based on Different Molecular Epidemiological Markers for Typing of Mycobacterium tuberculosis Complex Strains: Interlaboratory Study of Discriminatory Power and Reproducibility. Journal of Clinical Microbiology, 1999, 37, 2607-2618.	1.8	506
143	Multidrug-resistant tuberculosis caused by 'W'-related strains in three immunocompetent foreign-born patients. International Journal of Tuberculosis and Lung Disease, 1999, 3, 82-4.	0.6	10
144	Conjugating DNA into Mycobacteria. , 1998, 101, 119-128.		0

#	Article	IF	Citations
145	Molecular Cloning and Characterization of Tap, a Putative Multidrug Efflux Pump Present in Mycobacterium fortuitum and Mycobacterium tuberculosis. Journal of Bacteriology, 1998, 180, 5836-5843.	1.0	166
146	Allele-Specific PCR Method Based on pncA and oxyR Sequences for Distinguishing Mycobacterium bovis from Mycobacterium tuberculosis : Intraspecific M. bovis pncA Sequence Polymorphism. Journal of Clinical Microbiology, 1998, 36, 239-242.	1.8	71
147	The molecular epidemiology of tuberculosis in Zaragoza, Spain: a retrospective epidemiological study in 1993. International Journal of Tuberculosis and Lung Disease, 1998, 2, 281-7.	0.6	25
148	Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis. Aids, 1997, 11, 1237-1242.	1.0	76
149	Isolation by genetic labeling of a new mycobacterial plasmid, pJAZ38, from Mycobacterium fortuitum. Journal of Bacteriology, 1997, 179, 4115-4122.	1.0	36
150	katGI and katGII encode two different catalases-peroxidases in Mycobacterium fortuitum. Journal of Bacteriology, 1997, 179, 6880-6886.	1.0	19
151	Aminoglycoside 2â€²â€•N â€acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2 â€ƒâ€²)â€‰c gene from Mycobacterium tuberculosis and the aac(2 â€ƒâ€²)â€‰d gene from Mycobacterium smegmatis. Molecular Microbiology, 1997, 24, 431-441.	2.4	99
152	Use of a PCR method based on IS6110 polymorphism for typing Mycobacterium tuberculosis strains from BACTEC cultures. Journal of Clinical Microbiology, 1997, 35, 273-277.	1.8	25
153	Identification by spoligotyping of a caprine genotype in Mycobacterium bovis strains causing human tuberculosis. Journal of Clinical Microbiology, 1997, 35, 3328-3330.	1.8	74
154	Genetic characterization of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency virus-positive patients. Journal of Clinical Microbiology, 1997, 35, 1390-1393.	1.8	85
155	Construction of a family of Mycobacterium/Escherichia coli shuttle vectors derived from pAL5000 and pACYC184: their use for cloning an antibiotic-resistance gene from Mycobacterium fortuitum. Gene, 1996, 176, 23-26.	1.0	27
156	Characterization of the chromosomal aminoglycoside 2'-N-acetyltransferase gene from Mycobacterium fortuitum. Antimicrobial Agents and Chemotherapy, 1996, 40, 2350-2355.	1.4	43
157	The Mycobacterium tuberculosis purine biosynthetic pathway: isolation and characterization of the purC and purL genes. Microbiology (United Kingdom), 1996, 142, 2439-2447.	0.7	29
158	Use of conjugative and thermosensitive cloning vectors for transposon delivery toMycobacterium smegmatis. FEMS Microbiology Letters, 1995, 127, 35-39.	0.7	14
159	Differentiation by molecular typing of Mycobacterium bovis strains causing tuberculosis in cattle and goats. Journal of Clinical Microbiology, 1995, 33, 2953-2956.	1.8	75
160	Chromosomal DNA fingerprinting analysis using the insertion sequence IS6110 and the repetitive element DR as strain-specific markers for epidemiological study of tuberculosis in French Polynesia. Journal of Clinical Microbiology, 1995, 33, 1899-1904.	1.8	65
161	Insertion sequence IS1137, a new IS3 family element from Mycobacterium smegmatis. Microbiology (United Kingdom), 1994, 140, 2821-2828.	0.7	17
162	Efficient transposition in mycobacteria: construction of Mycobacterium smegmatis insertional mutant libraries. Journal of Bacteriology, 1994, 176, 535-539.	1.0	138

#	Article	IF	Citations
163	New Methods for Diagnosis and Epidemiological Studies of Tuberculosis based on PCR and RFLP. , 1994, , 105-113.		2
164	Onopordum nervosum as biomass source: Some aspects of its production and transformation by enzymatic hydrolysis. Bioresource Technology, 1993, 44, 95-99.	4.8	2
165	Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. Journal of Clinical Microbiology, 1993, 31, 406-409.	1.8	2,179
166	Analysis of the regions responsible for IS6110 RFLP in a single Mycobacterium tuberculosis strain. Research in Microbiology, 1992, 143, 767-772.	1.0	63
167	Isolation and analysis of IS6120, a new insertion sequence from Mycobacterium smegmatis. Molecular Microbiology, 1992, 6, 107-113.	1.2	60
168	Temperature-sensitive mutants of the Mycobacterium plasmid pAL5000. FEMS Microbiology Letters, 1992, 77, 181-6.	0.7	23
169	Transformation of Mycobacterium aurum and Mycobacterium smegmatis with the broad host-range Gram-negative cosmid vector pJRD215. Molecular Microbiology, 1991, 5, 1561-1566.	1.2	45
170	Site-specific integration of the Streptomyces plasmid pSAM2 in Mycobacterium smegmatis. Molecular Microbiology, 1991, 5, 2499-2502.	1.2	45
171	Restriction fragment length polymorphism analysis using IS6110 as an epidemiological marker in tuberculosis. Journal of Clinical Microbiology, 1991, 29, 1252-1254.	1.8	170
172	Transposition of an antibiotic resistance element in mycobacteria. Nature, 1990, 345, 739-743.	13.7	229
173	Effect of acid steam explosion on enzymatic hydrolysis ofO. nervosum andC. cardunculus. Applied Biochemistry and Biotechnology, 1990, 24-25, 127-134.	1.4	29
174	Effects of variation of inverted-repeat sequences on reactions mediated by the transposase of Tn21. Journal of Bacteriology, 1989, 171, 3996-4001.	1.0	6
175	Enzymatic hydrolysis of lignocellulosic biomass fromOnopordum nervosum. Biotechnology and Bioengineering, 1988, 32, 341-344.	1.7	10
176	Factors that affect transposition mediated by the Tn21 transposase. Plasmid, 1988, 20, 54-60.	0.4	4
177	Structure and mobilization of an ampicillin and gentamicin resistance determinant. Antimicrobial Agents and Chemotherapy, 1987, 31, 1266-1270.	1.4	18
178	Aminoglycoside-phosphotransferases APH(3â€²)-IV and APH(3â€³) synthesized by a strain of Campylobacter coli. Journal of Antimicrobial Chemotherapy, 1986, 18, 153-158.	1.3	66
179	The Lack of the TetR-Like Repressor Gene BCG_2177c (Rv2160A) May Help Mycobacteria Overcome Intracellular Redox Stress and Survive Longer Inside Macrophages When Surrounded by a Lipid Environment. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	0